- Home
- CCCC vs ZNTL Comparison
CCCC vs ZNTL Comparison
Compare CCCC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- ZNTL
- Stock Information
- Founded
- CCCC 2015
- ZNTL 2014
- Country
- CCCC United States
- ZNTL United States
- Employees
- CCCC N/A
- ZNTL N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- CCCC Health Care
- ZNTL Health Care
- Exchange
- CCCC Nasdaq
- ZNTL Nasdaq
- Market Cap
- CCCC 104.4M
- ZNTL 105.8M
- IPO Year
- CCCC 2020
- ZNTL 2020
- Fundamental
- Price
- CCCC $2.35
- ZNTL $1.37
- Analyst Decision
- CCCC Buy
- ZNTL Buy
- Analyst Count
- CCCC 3
- ZNTL 7
- Target Price
- CCCC $12.00
- ZNTL $8.60
- AVG Volume (30 Days)
- CCCC 1.6M
- ZNTL 1.4M
- Earning Date
- CCCC 07-31-2025
- ZNTL 08-08-2025
- Dividend Yield
- CCCC N/A
- ZNTL N/A
- EPS Growth
- CCCC N/A
- ZNTL N/A
- EPS
- CCCC N/A
- ZNTL N/A
- Revenue
- CCCC $39,783,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- CCCC N/A
- ZNTL N/A
- Revenue Next Year
- CCCC N/A
- ZNTL N/A
- P/E Ratio
- CCCC N/A
- ZNTL N/A
- Revenue Growth
- CCCC 98.56
- ZNTL N/A
- 52 Week Low
- CCCC $1.09
- ZNTL $1.01
- 52 Week High
- CCCC $7.66
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- CCCC 63.62
- ZNTL 52.54
- Support Level
- CCCC $1.36
- ZNTL $1.29
- Resistance Level
- CCCC $2.17
- ZNTL $1.38
- Average True Range (ATR)
- CCCC 0.15
- ZNTL 0.09
- MACD
- CCCC 0.05
- ZNTL 0.01
- Stochastic Oscillator
- CCCC 67.11
- ZNTL 84.62
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.